FDA backs combination treatment for gout
medwireNews: The US FDA has approved a dual therapy combining lesinurad and allopurinol for the treatment of hyperuricemia associated with gout.
A once-daily oral dose, containing 200 mg of the URAT1 inhibitor lesinurad and 300 mg of the xanthine oxidase inhibitor allopurinol, is indicated for gout patients who have not achieved target serum uric acid levels with allopurinol alone.
The FDA cautions that the combination should not be used for the treatment of asymptomatic hyperuricemia, and the prescribing information contains a boxed warning for acute renal failure. A formulation containing a lower dose of 200 mg lesinurad/200 mg allopurinol will be available for patients with renal impairment.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2017 Springer Healthcare part of the Springer Nature group